SEC says insider made $10M on Abbott, CFR deal

Nonpublic information about Abbott's ($ABT) May agreement to buy CFR Pharmaceuticals helped score a former CFR board member a hefty profit, according to U.S. regulators. And they're charging him with insider trading.

On Monday, the SEC filed a civil lawsuit accusing former director Juan Cruz Bilbao Hormaeche of racking up more than $10.1 million through trades on private information he learned during board meetings that preceded the deal, Reuters reports. The lawsuit also charges a business associate of Bilbao's who allegedly processed transactions for Bilbao and himself, earning $500,000 in the process.

According to regulators, after learning of Abbott's offer in mid-March, Bilbao used his associate to buy up more than 700,000 American depository shares of CFR totaling $14.35 million in the name of a Virgin Islands entity, with the associate buying $700,000 worth of CFR shares of his own. After Abbott announced the acquisition and CFR's stock price rose, they tendered those shares to make a profit.

This isn't the first deal in a banner M&A year for pharma to produce insider trading charges. Back in October, for one, the SEC and federal prosecutors filed a civil and criminal complaint against a former Merck ($MRK) employee who they said used info from confidential files to have a friend make trades on future buyout target Idenix.

- get more from Reuters

Special Report: Pharma's top 10 M&A deals of 2014's first halfAbbott/CFR

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.